X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
anti-adalimumab antibodies (53) 53
humans (48) 48
index medicus (48) 48
rheumatology (29) 29
rheumatoid arthritis (28) 28
infliximab (27) 27
immunogenicity (26) 26
adalimumab (25) 25
arthritis, rheumatoid - drug therapy (24) 24
antirheumatic agents - therapeutic use (21) 21
clinical-response (20) 20
treatment outcome (19) 19
male (18) 18
middle aged (18) 18
adult (17) 17
female (17) 17
tumor necrosis factor-alpha - antagonists & inhibitors (17) 17
efficacy (16) 16
crohns-disease (15) 15
etanercept (15) 15
methotrexate (15) 15
double-blind (14) 14
rheumatoid-arthritis (14) 14
pharmacology & pharmacy (13) 13
ankylosing-spondylitis (11) 11
care and treatment (11) 11
therapeutic drug monitoring (11) 11
arthritis, rheumatoid - immunology (10) 10
biological products - therapeutic use (10) 10
drug monitoring - methods (10) 10
monoclonal antibodies (10) 10
aged (9) 9
antirheumatic agents - immunology (9) 9
biological products (9) 9
psoriasis (9) 9
antibodies (8) 8
antibodies, monoclonal - immunology (8) 8
antibodies, monoclonal - therapeutic use (8) 8
antirheumatic agents - administration & dosage (8) 8
therapy (8) 8
animals (7) 7
ankylosing spondylitis (7) 7
antibodies, monoclonal, humanized - therapeutic use (7) 7
antitumor necrosis factor (7) 7
arthritis, rheumatoid - blood (7) 7
disease-activity (7) 7
immunoglobulins (7) 7
immunology (7) 7
inadequate response (7) 7
inflammatory diseases (7) 7
necrosis-factor-alpha (7) 7
rheumatoid-arthritis patients (7) 7
severity of illness index (7) 7
abridged index medicus (6) 6
antibodies - blood (6) 6
antibodies, monoclonal, humanized - administration & dosage (6) 6
antibodies, monoclonal, humanized - immunology (6) 6
antirheumatic agents - adverse effects (6) 6
antirheumatic agents - blood (6) 6
drug therapy, combination (6) 6
injections, subcutaneous (6) 6
methotrexate - therapeutic use (6) 6
monoclonal-antibody (6) 6
spondylitis, ankylosing - drug therapy (6) 6
anti-adalimumab (5) 5
anti-adalimumab antibody (5) 5
anti-drug antibodies (5) 5
antibodies, monoclonal, humanized - adverse effects (5) 5
antirheumatic agents - pharmacokinetics (5) 5
arthritis (5) 5
arthritis, psoriatic - drug therapy (5) 5
biopharmaceuticals (5) 5
cross-sectional studies (5) 5
enzyme-linked immunosorbent assay (5) 5
gastroenterology & hepatology (5) 5
inflammatory bowel disease (5) 5
inflammatory bowel diseases - drug therapy (5) 5
long-term treatment (5) 5
medicine & public health (5) 5
patients (5) 5
pharmacokinetics (5) 5
phase-iii (5) 5
placebo-controlled trial (5) 5
rheumatoid factor (5) 5
safety (5) 5
tnf inhibitors (5) 5
tumor necrosis factor-tnf (5) 5
young adult (5) 5
abatacept (4) 4
active rheumatoid-arthritis (4) 4
agents (4) 4
analysis (4) 4
anti-infliximab (4) 4
anti-infliximab antibodies (4) 4
antibodies, monoclonal, humanized - blood (4) 4
antirheumatic agents (4) 4
biological products - blood (4) 4
biopharmaceutics (4) 4
crohn disease - drug therapy (4) 4
dermatology (4) 4
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2014, Volume 73, Issue 6, pp. 1138 - 1143
Journal Article
Journal of Rheumatology, ISSN 0315-162X, 01/2015, Volume 42, Issue 1, pp. 73 - 78
Journal Article
International Immunopharmacology, ISSN 1567-5769, 07/2014, Volume 21, Issue 1, pp. 20 - 25
Journal Article
Therapeutic Drug Monitoring, ISSN 0163-4356, 08/2017, Volume 39, Issue 4, pp. 364 - 369
Journal Article
Journal Article
BioDrugs, ISSN 1173-8804, 08/2017, Volume 31, Issue 4, pp. 299 - 316
Objectives A systematic review was conducted to explore the immunogenicity of biologic agents across inflammatory diseases and its potential impact on... 
ACTIVE RHEUMATOID-ARTHRITIS | IMMUNOLOGY | DECREASED CLINICAL-RESPONSE | INTRAVENOUS GOLIMUMAB THERAPY | ANTITUMOR NECROSIS FACTOR | ANTI-ADALIMUMAB ANTIBODIES | INFLIXIMAB TROUGH LEVELS | ONCOLOGY | PHARMACOLOGY & PHARMACY | PLACEBO-CONTROLLED TRIAL | METHOTREXATE-NAIVE PATIENTS | LONG-TERM TREATMENT | POST-HOC ANALYSIS | Biosimilar Pharmaceuticals - therapeutic use | Humans | Spondylitis, Ankylosing - drug therapy | Anti-Inflammatory Agents, Non-Steroidal - immunology | Antibodies, Monoclonal - therapeutic use | Infliximab - therapeutic use | Ustekinumab - therapeutic use | Arthritis, Juvenile - drug therapy | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Arthritis, Rheumatoid - drug therapy | Abatacept - therapeutic use | Arthritis, Psoriatic - drug therapy | Crohn Disease - drug therapy | Colitis, Ulcerative - drug therapy | Antibodies, Monoclonal - immunology | Antirheumatic Agents - therapeutic use | Etanercept - therapeutic use | Immunoassay | Inflammatory bowel diseases | Medical services | Systematic review | Arthritis | Inflammatory diseases | Proteins | Literature reviews | Infusion | Etanercept | Infliximab | Tumor necrosis factor-TNF | Ankylosing spondylitis | Immunoglobulins | Biological products | Psoriasis | Publications | Dermatology | Decision making | Rheumatology | Rheumatic diseases | Rituximab | Crohn's disease | Tumor necrosis factor-α | Patients | Diseases | Crohns disease | Inflammatory bowel disease | Studies | Spondylitis | Immunogenicity | Rheumatoid arthritis | Monoclonal antibodies | TNF inhibitors | Ulcerative colitis
Journal Article
Drug Development Research, ISSN 0272-4391, 11/2014, Volume 75, Issue 1, pp. S11 - S14
Enabling Technology, Genomics, Proteomics Clinical Development Phases I‐III Regulatory, Quality, Manufacturing Psoriasis (Ps) is a common and stigmatizing... 
serum concentrations | assay | adalimumab